Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on shareholders\' voluntary commitment to extend the share lockdown period
Yahong Pharmaceutical: Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on the release of data related to the APL-1702 international multi-center phase III clinical trial at the 2024 International Papillomavirus Conference
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement that APL-1706 was approved for marketing by the State Drug Administration
Yahong Pharmaceutical: Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on completing the industrial and commercial registration of the change in the company\'s business scope and issuing a business license
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on changing the sponsor representative for continuous supervision
Yahong Pharmaceutical: Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on the progress of repurchasing the company\'s shares through centralized bidding
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on the release of data related to the APL-1702 international multi-center phase III clinical trial at the 27th National Clinical Oncology Conference and the 2024 CSCO Academic Annual Conference
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the results of the Phase II clinical trial of APL-1202 oral combined with tiralizumab as a new adjuvant treatment for muscle-invasive bladder cancer
Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Legal Opinion of Beijing Jiayuan Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. voluntarily disclosed the announcement on the release of data related to the APL-1702 international multi-center phase III clinical trial at the 2024 International Photodynamics and Photodiagnosis Conference
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Second Extraordinary General Meeting of Shareholders Meeting Data
Notice of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on convening the 2nd Extraordinary General Meeting of Shareholders in 2024
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on changing some fund-raising investment projects
“Constitution of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.” (revised in August 2024)
Announcement of Jiangsu Yahong Pharmaceutical Technology Co., Ltd. on increasing the company\'s business scope and revising the “Articles of Association”
Announcement on Completing the Business Registration for the Change of Business Scope and Issuing a New Business License of Jiangsu Yahong Medical Technology Co., Ltd.
Legal Opinion on the 2023 Annual Shareholders Meeting of Jiangsu YAHONG Medical Technology Co., Ltd. by Jiayuan Law Firm, Peking.